The UC Davis Cancer Center, the only NCI-designated cancer center in the Central Valley of California, is the advanced cancer care provider for a population of five million, the only significance point of access to early phase cancer clinical trials in its Northern California region, and together with its collaborator, the Lawrence Livermore National Laboratory [LLNL], the region's principal cancer research organization. Since its founding thirteen years ago, the UC Davis Cancer Center has provided increasingly progressive leadership to, organization of, and support for cancer investigation. In the first sections, we recapitulate briefly the milestones leading up to NCI designation (July 1, 2002). In subsequent sections, we focus on decisions, achievements, and directions characterizing the center's first two years of its Cancer Center Support Grant [CCSG]. In concluding sections, we focus on program and organizational accomplishments, future direction, and geography.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-08S4
Application #
8119800
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2002-07-01
Project End
2011-06-30
Budget Start
2010-08-28
Budget End
2011-06-30
Support Year
8
Fiscal Year
2010
Total Cost
$2,993,642
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116
Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343
Xue, Xiangdong; Huang, Yee; Wang, Xinshuai et al. (2018) Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 161:203-215
Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506
Zuo, Yang; Qi, Jinyi; Wang, Guobao (2018) Relative Patlak plot for dynamic PET parametric imaging without the need for early-time input function. Phys Med Biol 63:165004
McGee, Heather M; Daly, Megan E; Azghadi, Sohelia et al. (2018) Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 101:1259-1270
Klapheke, Amy; Yap, Stanley A; Pan, Kevin et al. (2018) Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol 36:308.e19-308.e25
Pol, Arjan; Renkema, G Herma; Tangerman, Albert et al. (2018) Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause extraoral halitosis. Nat Genet 50:120-129
Wang, Yuru; Park, SeHee; Beal, Peter A (2018) Selective Recognition of RNA Substrates by ADAR Deaminase Domains. Biochemistry 57:1640-1651
Campbell, Mel; Watanabe, Tadashi; Nakano, Kazushi et al. (2018) KSHV episomes reveal dynamic chromatin loop formation with domain-specific gene regulation. Nat Commun 9:49

Showing the most recent 10 out of 836 publications